Literature DB >> 28715536

Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.

María Inés Gaitán1, María Célica Ysrraelit1, Jorge Correale1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28715536     DOI： 10.1001/jamaneurol.2017.1456

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  9 in total

1.  Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.

Authors:  Simonetta Galgani; Luca Prosperini; Shalom Haggiag; Carla Tortorella; Claudio Gasperini
Journal:  J Neurol       Date:  2018-07-17       Impact factor: 4.849

2.  Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis.

Authors:  Georgia McCaughan; Jennifer Massey; Ian Sutton; Jennifer Curnow
Journal:  BMJ Case Rep       Date:  2017-12-05

Review 3.  Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors:  Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

4.  A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.

Authors:  A G Vakrakou; D Tzanetakos; S Valsami; E Grigoriou; K Psarra; J Tzartos; M Anagnostouli; E Andreadou; M E Evangelopoulos; G Koutsis; C Chrysovitsanou; E Gialafos; A Dimitrakopoulos; L Stefanis; C Kilidireas
Journal:  BMC Neurol       Date:  2018-10-29       Impact factor: 2.474

Review 5.  Neutrophils: Underestimated Players in the Pathogenesis of Multiple Sclerosis (MS).

Authors:  Mirre De Bondt; Niels Hellings; Ghislain Opdenakker; Sofie Struyf
Journal:  Int J Mol Sci       Date:  2020-06-26       Impact factor: 5.923

Review 6.  The Emerging Role of Neutrophil Granulocytes in Multiple Sclerosis.

Authors:  Tonia Woodberry; Sophie E Bouffler; Alicia S Wilson; Rebecca L Buckland; Anne Brüstle
Journal:  J Clin Med       Date:  2018-12-03       Impact factor: 4.241

7.  Emerging safety issues in alemtuzumab-treated MS patients.

Authors:  Joep Killestein; Bob van Oosten
Journal:  Mult Scler       Date:  2019-08       Impact factor: 6.312

Review 8.  State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies.

Authors:  Emmanuel Andrès; Noel Lorenzo Villalba; Abrar-Ahmad Zulfiqar; Khalid Serraj; Rachel Mourot-Cottet; And Jacques-Eric Gottenberg
Journal:  J Clin Med       Date:  2019-09-01       Impact factor: 4.241

9.  Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis.

Authors:  Hans-Klaus Goischke
Journal:  Ther Clin Risk Manag       Date:  2019-07-12       Impact factor: 2.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.